1) Rennenberg R, Kessels A, Schurgers, Van Engelshoven J,
de Leeuw P, Kroon A. Vascular calcifications as a marker
of increased cardiovascular risk: a meta-analysis. Vasc
Health Risk Manag, 2009; 5: 185-197
2) Raggi P, Bellasi A, Gamboa C, Ferramosca E, Ratti C,
Block GA, Muntner P. All-cause mortality in hemodialysis
patients with heart valve calcification. Clin J Am Soc
Nephrol, 2011; 6: 1990-1995
3) Kitamura K, Fujii H, Nakai K, Kono K, Goto S, Nishii T,
Kono A, Nishi S. Relationship between cardiac
calcification and left ventricular hypertrophy in patients
with chronic kidney disease at hemodialysis initiation.
Heart Vessels, 2017; 32: 1109-1116
4) Mehta A, Pandey A, Ayers CR, Khera A, Sperling LS,
Szklo MS, Gottesman RF, Budoff MJ, Blaha MJ,
Blumenthal RS, Nasir K, Joshi PH. Predictive Value of
Coronary Artery Calcium Score Categories for Coronary
Events Versus Strokes: Impact of Sex and Race: MESA
and DHS. Circ Cardiovasc Imaging, 2020; 13: e010153
5) Lei MH, Wu YL, Chung SL, Chen CC, Chen WC, Hsu
YC. Coronary Artery Calcium Score Predicts Long-Term
Cardiovascular Outcomes in Asymptomatic Patients with
Type 2 Diabetes. J Atheroscler Thromb, 2021; 28: 10521062
6) Drüeke TB, Massy ZA. Atherosclerosis in CKD:
differences from the general population. Nat Rev
Nephrol, 2010; 6: 723-735
7) Chade AR, Lerman A, Lerman LO. Kidney in early
atherosclerosis. Hypertension, 2005; 45: 1042-1049
8) Kon V, Linton MF, Fazio S. Atherosclerosis in chronic
kidney disease: the role of macrophages. Nat Rev
Nephrol, 2011; 7: 45-54
9) Fujii H, Goto S, Fukagawa M. Role of Uremic Toxins for
Kidney, Cardiovascular, AND Bone Dysfunction. Toxins,
2018; 10: 202
10) Shang D, Xie Q, Ge X, Yan H, Tian J, Kuang D, Hao
CM, Zhu T. Hyperphosphatemia as an independent risk
factor for coronary artery calcification progression in
peritoneal dialysis patients. BMC Nephrol, 2015; 16: 107
11) Adeney KL, Siscovick DS, Ix JH, et al. Association of
serum phosphate with vascular and valvular calcification
in moderate CKD. J Am Soc Nephrol, 2009; 20: 381387
12) Taniguchi M, Fukagawa M,Fujii N, Hamano T, Shoji T,
Yokoyama K, Nakai S, Shigematsu T, Iseki K, Tsubakihara
Y. Serum phosphate and calcium should be primarily and
consistently controlled in prevalent hemodialysis patients.
Ther Apher Dial, 2013; 17: 221-228
13) Dhingra R, Sullivan LM, Fox CS, Wang TJ, D’Agostino
RB Sr, Gaziano JM, Vasan RS. Relations of serum
phosphorus and calcium levels to the incidence of
cardiovascular disease in the community. Arch Intern
Med, 2007; 167: 879-885
14) Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation
between serum phosphate level and cardiovascular event
rate in people with coronary disease. Circulation, 2005;
112: 2627-2633
15) KDIGO 2017 Clinical Practice Guideline Update for the
Diagnosis, Evaluation, Prevention, and Treatment of
Chronic Kidney Disease-Mineral and Bone Disorder
(CKD-MBD). Kidney Int Suppl (2011), 2017: 7; 1-59
16) Fujii H, Kono K, Nakai K, Goto S, Tatsuya Nishii T,
Kono A, Nishi S. Effects of Lanthanum Carbonate on
Coronary Artery Calcification and Cardiac Abnormalities
After Initiating Hemodialysis. Calcif Tissue Int, 2018;
102: 310-320
17) Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji
T, Kazama JJ, Komaba H, Ando R, Kakuta T, Fujii H,
Nakayama M, Shibagaki Y, Fukumoto S, Fujii N, Hattori
M, Ashida A, Iseki K, Shigematsu T, Tsukamoto Y,
Tsubakihara Y, Tomo T, Hirakata H, Akizawa T. Clinical
practice guideline for the management of chronic kidney
disease-mineral and bone disorder. Ther Apher Dial,
2013; 17: 247-288
18) Lopes MB, Karaboyas A, Bieber B, Pisoni RL, Walpen S,
1575
Shimizu et al.
Fukagawa M, Christensson A, Evenepoel P, Pegoraro M,
Robinson BM, Pecoits-Filho R. Impact of longer term
phosphorus control on cardiovascular mortality in
hemodialysis patients using an area under the curve
approach: results from the DOPPS. Nephrol Dial
Transplant, 2020; 35: 1794-1801
19) Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR,
Viamonte M Jr, Detrano R. Quantification of coronary
artery calcium using ultrafast computed tomography. J
Am Coll Cardiol, 1990; 15: 827-832
20) Watanabe K, Fujii H, Kono K, Goto S, Nishi S.
Comparison of the effects of lanthanum carbonate and
calcium carbonate on the progression of cardiac valvular
calcification after initiation of hemodialysis. BMC
Cardiovasc Disord, 2020; 20: 39
21) Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y,
Mori K, Morii H, Giachelli CM. Phosphate regulation of
vascular smooth muscle cell calcification. Circ Res, 2000;
87: E10-17
22) Jimbo R, Kawakami-Mori F, Mu S, Hirohama D, Majtan
B, Shimizu Y, Yatomi Y, Fukumoto S, Fujita T, Shimosawa
T. Fibroblast growth factor 23 accelerates phosphateinduced vascular calcification in the absence of Klotho
deficiency. Kidney Int, 2014; 85: 1103-1111
23) Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ,
Demer LL, Heistad DD, Simmons CA, Masters KS,
Mathieu P, O’Brien KD, Schoen FJ, Towler DA,
Yoganathan AP, Otto CM. Calcific aortic valve disease:
not simply a degenerative process: A review and agenda
for research from the National Heart and Lung and Blood
Institute Aortic Stenosis Working Group. Executive
summary: Calcific aortic valve disease-2011 update.
Circularion, 2011; 124: 1783-1791
24) Otto CM. Calcific aortic stenosis--time to look more
closely at the valve. N Engl J Med, 2008; 359: 1395-1398
25) Reynolds JL, Joannides AJ, Skepper JN, McNair R,
Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg
PL, Shanahan CM. Human vascular smooth muscle cells
undergo vesicle-mediated calcification in response to
changes in extracellular calcium and phosphate
concentrations: a potential mechanism for accelerated
vascular calcification in ESRD. J Am Soc Nephrol, 2004;
15: 2857-2867
26) Phan O, Ivanovski O, Nguyen-Khoa T, Mothu N, Angulo
J, Westenfeld R, Ketteler M, Meert N, Maizel J, Nikolov
IG, Vanholder R, Lacour B, Drüeke TB, Massy ZA.
Sevelamer prevents uremia-enhanced atherosclerosis
progression in apolipoprotein E-deficient mice.
1576
Circulation, 2005; 112: 2875-2882
27) Lanzer P, Hannan FM, Lanzer JD, Janzen J, Raggi P,
Furniss D, Schuchardt M, Thakker R, Fok PW, SaezRodriguez J, Millan A, Sato Y, Ferraresi R, Virmani R, St
Hilaire C. Medial Arterial Calcification: JACC State-ofthe-Art Review. J Am Coll Cardiol, 2021; 78: 1145-1165
28) Fujii H, Kono K, Nishi S. Characteristics of coronary
artery disease in chronic kidney disease. Clin Exp
Nephrol, 2019; 23: 725-732
29) Linefsky JP, O’Brien KD, Sachs M, Katz R, Eng J, Michos
ED, Budoff MJ, de Boer IH, Kestenbaum B. Serum
phosphate is associated with aortic valve calcification in
the Multi-ethnic Study of Atherosclerosis (MESA).
Atherosclerosis, 2014; 233: 331-337
30) Linefsky JP, O’Brien KD, Katz R, de Boer IH, Barasch E,
Jenny NS, Siscovick DS, Kestenbaum B. Association of
serum phosphate levels with aortic valve sclerosis and
annular calcification: the cardiovascular health study. J
Am Coll Cardiol, 2011; 58: 291-297
31) Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie
EG, Chertow GM. Mineral metabolism, mortality, and
morbidity in maintenance hemodialysis. J Am Soc
Nephrol, 2004; 15: 2208-2218
32) Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus,
parathyroid hormone, and cardiovascular disease in
hemodialysis patients: the USRDS waves 1, 3, and 4
study. J Am Soc Nephrol, 2005; 16: 1788-1793
33) Fernández-Martín JL, Martínez-Camblor P, Dionisi MP,
Floege J, Ketteler M, London G, Locatelli F, Gorriz JL,
Rutkowski B, Ferreira A, Bos WJ, Covic A, RodríguezGarcía M, Sánchez JE, Rodríguez-Puyol D, CannataAndia JB. Fernández-Martín JL, et al. Improvement of
mineral and bone metabolism markers is associated with
better survival in haemodialysis patients: the COSMOS
study. Nephrol Dial Transplant, 2015; 30: 1542-1551
34) Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M,
Tominaga Y, Iseki K, Tsubakihara Y. Effects of serum
calcium, phosphorous, and intact parathyroid hormone
levels on survival in chronic hemodialysis patients in
Japan. Ther Apher Dial, 2008; 12: 49-54
35) Isaka Y, Hamano T, Fujii H, Tsujimoto Y, Koiwa F,
Sakaguchi Y, Tanaka R, Tomiyama N, Tatsugami F,
Teramukai S. Optimal Phosphate Control Related to
Coronary Artery Calcification in Dialysis Patients. J Am
Soc Nephrol, 2021; 32: 723-735
36) Martin KJ. How to evaluate phosphate control in patients
on dialysis. Nephrol Dial Transplant, 2022; 37: 18301832
Phosphate Control and Calcification
Supplementary Table 1. Clinical characteristics depending on the serum phosphate excursions
Age (year)
Male (%)
Smoking (%)
HT (%)
DM (%)
DLp (%)
SBP (mmHg)
DBP (mmHg)
ACE-I/ARB (%)
Statin (%)
Lanthanum carbonate (%)
Calcium carbonate (%)
Sevelamer (%)
Bixalomer (%)
Vitamin D (%)
Warfarin (%)
Hb (g/dL)
cCa (mg/dL)
P (mg/dL)
Albumin (g/dL)
Intact PTH (pg/mL)
CACS
CVCS
All (n = 33)
0 times (n = 8)
3 times (n = 25)
67.9±9.9
27 (81.8)
14 (42.4)
33 (100)
17 (51.5)
9 (27.3)
150.1±23.1
74.9±14.9
19 (57.6)
12 (36.4)
18 (54.5)
15 (45.5)
0 (0.0)
0 (0.0)
10 (30.3)
2 (6.1)
8.8±1.3
8.7±0.6
5.5±1.3
3.4±0.5
239.0 (134.7 – 397.2)
632.4 (131.8 – 1144.5)
2.0 (0.0 – 2.25)
74.1±10.2
8 (100)
3 (37.5)
8 (100)
3 (37.5)
0 (0.0)
149.7±20.2
76.9±14.4
4 (50.0)
2 (25.0)
4 (50.0)
4 (50.0)
0 (0.0)
0 (0.0)
2 (25.0)
1 (12.5)
9.2±0.8
8.5±0.4
4.7±1.6
3.5±0.6
252.6 (95.9 – 500.5)
864.8 (219.1 – 1927.3)
1.0 (0.0 – 2.75)
65.9±9.1
19 (76.0)
11 (44.0)
25 (100)
14 (56.0)
9 (36.0)
150.2±24.3
74.4±15.2
15 (60.0)
10 (40.0)
14 (56.0)
11 (44.0)
0 (0.0)
0 (0.0)
8 (32.0)
1 (4.0)
8.7±1.4
8.8±0.6
5.8±1.0
3.3±0.4
239.0 (140.2 – 397.2)
632.4 (108.4 – 1098.5)
2.0 (0.0 – 2.25)
0.038
0.160
0.539
0.307
0.053
0.959
0.706
0.461
0.373
0.541
0.541
0.539
0.432
0.074
0.279
0.018
0.444
0.848
0.352
0.721
AUC, area under the curve; HT, hypertension; DM, diabetes mellitus; DLp, dyslipidemia; SBP, systolic blood pressure; DBP, diastolic blood
pressure; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; Hb, hemoglobin; cCa, corrected calcium; P,
phosphate; PTH, parathyroid hormone; CACS, coronary artery calcium score; CVCS, cardiac valvular calcification score.
Values are presented as mean±SD or median (interquartile range).
Supplementary Table 2. Correlation of vascular and valvular calcifications with clinical factors
ΔCACS
Univariate
Age
Gender
AUC
baseline CACS
ΔCVCS
Multivariate
Univariate
Multivariate
-0.189
0.013
0.299
-0.081
0.135
0.922
0.016
0.525
-0.159
0.087
0.271
-0.003
0.263
0.510
0.035
0.983
0.156
0.148
0.394
-0.216
0.377
0.405
0.021
0.219
0.237
-0.005
0.401
-0.145
0.217
0.979
0.025
0.447
1577
Shimizu et al.
Supplementary Table 3. Clinical characteristics between the low AUC and high AUC groups among patients with CVCS
Age (year)
Male (%)
Smoking (%)
HT (%)
DM (%)
DLp (%)
SBP (mmHg)
DBP (mmHg)
ACE-I/ARB (%)
Statin (%)
Lanthanum carbonate (%)
Calcium carbonate (%)
Sevelamer (%)
Bixalomer (%)
Vitamin D (%)
Warfarin (%)
Hb (g/dL)
cCa (mg/dL)
P (mg/dL)
Albumin (g/dL)
Intact PTH (pg/mL)
CACS
CVCS
All (n = 34)
Low AUC (n = 17)
High AUC (n = 17)
69.4±9.2
26 (78.1)
22 (64.7)
34 (100.0)
16 (47.1)
16 (47.1)
145.2±19.3
68.4±11.1
23 (45.3)
23 (67.6)
16 (47.1)
18 (52.9)
0 (0.0)
0 (0.0)
11 (32.4)
3 (8.8)
8.7±1.2
8.8±0.5
5.7±1.3
3.3±0.4
235.0 (133.0 – 335.0)
549.7 (141.8 – 1221.2)
2.0 (0.0 – 3.0)
70.9±10.0
13 (76.5)
12 (70.6)
17 (100.0)
7 (41.2)
6 (35.3)
144.5±16.9
69.7±10.8
11 (64.7)
10 (58.8)
7 (41.2)
10 (58.8)
0 (0.0)
0 (0.0)
4 (23.5)
2 (11.8)
8.7±1.3
8.8±0.7
5.3±1.4
3.2±0.4
262.0 (109.0 – 389.0)
480.7 (142.5 – 1840.9)
2.0 (0.5 – 4.0)
67.8±8.4
13 (76.5)
10 (58.8)
17 (100.0)
9 (52.9)
10 (58.8)
145.9±22.0
67.1±11.5
12 (70.6)
13 (76.5)
9 (52.9)
8 (47.1)
0 (0.0)
0 (0.0)
7 (41.2)
1 (5.9)
8.9±1.2
8.7±0.4
6.2±0.9
3.4±0.5
231.0 (157.0 – 330.0)
618.7 (131.8 – 1074.9)
2.0(0.0 – 2.5)
0.342
0.656
0.473
0.492
0.169
0.828
0.503
0.714
0.271
0.492
0.492
0.271
0.500
0.568
0.469
0.029
0.425
0.973
0.518
0.231
AUC, area under the curve; HT, hypertension; DM, diabetes mellitus; DLp, dyslipidemia; SBP, systolic blood pressure; DBP, diastolic blood
pressure; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; Hb, hemoglobin; cCa, corrected calcium; P,
phosphate; PTH, parathyroid hormone; CACS, coronary artery calcium score; CVCS, cardiac valvular calcification score.
Values are presented as mean±SD or median (interquartile range).
1578
Phosphate Control and Calcification
Supplementary Table 4. Clinical characteristics depending on the serum phosphate excursions among patients with CVCS
Age (year)
Male (%)
Smoking (%)
HT (%)
DM (%)
DLp (%)
SBP (mmHg)
DBP (mmHg)
ACE-I/ARB (%)
Statin (%)
Lanthanum carbonate (%)
Calcium carbonate (%)
Sevelamer (%)
Bixalomer (%)
Vitamin D (%)
Warfarin (%)
Hb (g/dL)
cCa (mg/dL)
P (mg/dL)
Albumin (g/dL)
Intact PTH (pg/mL)
CACS
CVCS
All (n = 18)
0 time (n = 4)
3 times (n = 14)
70.0±9.2
15 (83.3)
11 (61.1)
18 (100.0)
8 (44.4)
7 (38.9)
145.7±20.3
67.6±10.2
11 (61.1)
12 (66.7)
10 (55.6)
8 (44.4)
0 (0.0)
0 (0.0)
7 (38.9)
2 (11.1)
9.0±1.1
8.6±0.4
5.7±1.2
3.4±0.5
235.0 (158.8 – 335.0)
510.1 (139.4 – 1122.0)
2.0 (0.0 – 2.25)
78.3±6.7
4 (100.0)
3 (75.0)
4 (100.0)
2 (50.0)
0 (0.0)
144.3±20.9
66.8±6.7
2 (50.0)
2 (50.0)
2 (50.0)
2 (50.0)
0 (0.0)
0 (0.0)
2 (50.0)
1 (25.0)
9.2±0.8
8.3±0.2
4.3±1.1
3.4±0.4
161.0 (36.8 – 484.8)
821.4 (219.1 – 1927.3)
1.0 (0.0 – 2.75)
67.6±8.5
11 (78.6)
8 (57.1)
14 (100.0)
6 (42.9)
7 (50.0)
146.1±20.9
67.8±11.2
9 (64.3)
10 (71.4)
8 (57.1)
6 (42.9)
0 (0.0)
0 (0.0)
5 (35.7)
1 (7.1)
8.9±1.3
8.7±0.4
6.1±1.0
3.4±0.5
239.0 (179.0 – 335.0)
495.8 (104.5 – 1058.7)
2.0 (0.0 – 2.25)
0.018
0.446
0.485
0.618
0.108
0.875
0.864
0.515
0.407
0.618
0.618
0.515
0.405
0.705
0.053
0.005
0.979
0.442
0.327
0.721
AUC, area under the curve; HT, hypertension; DM, diabetes mellitus; DLp, dyslipidemia; SBP, systolic blood pressure; DBP, diastolic blood
pressure; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; Hb, hemoglobin; cCa, corrected calcium; P,
phosphate; PTH, parathyroid hormone; CACS, coronary artery calcium score; CVCS, cardiac valvular calcification score.
Values are presented as mean±SD or median (interquartile range).
1579
...
論文の公開元へ
